Devatis AG was founded in 2018 in Cham, Switzerland. Behind Devatis AG is EastPharma Ltd, which was established in 2006 with the aim of becoming a major player in the fast growing emerging markets pharmaceutical industry and had been listed on London Stock Exchange (LSE) between 2008 and August 2019.
DEVA Holding, pioneering Turkish pharmaceutical company, was founded in 1958 by group of medical doctors and pharmacists with main scope of business including manufacturing and marketing of high quality pharmaceutical finished products and active ingredients. Company has export operations to approximately 50 countries worldwide.
Our Philosophy: We are committed to improving access to quality medicines.
Our Corporate Goal: Continuous growth by expanding our product portfolio to establish a strong brand.
DEVA Holding A.Ş. was founded in 1958 by a group of doctors, pharmacists and veterinarians. Since 1986 DEVA Holding shares have been traded on Istanbul Stock Exchange. Majority shares of DEVA Holding were acquired in 2006 by the funds managed by GEM Global Equities Management S.A., an international fund management company, and EastPharma Ltd. was established to take on the management.
With its main scope of business covering manufacturing and marketing of medicines for human use and raw materials, DEVA Holding also produces veterinary drugs, medical vials. Having a strong presence in the domestic market, DEVA Holding also exports finished products and raw materials to approximately 50 countries worldwide.
Growing over 60 years in the Turkish pharmaceutical market, DEVA, with its broad product portfolio in different therapeutic areas, became one of the leading pharmaceutical companies in Turkey. With its three EU-GMP accredited manufacturing facilities, approximately 2400 employees and state-of-the-art R&D centre DEVA targets to become a world-class player. Focusing on developing innovative new forms and products of high added value, DEVA allocated approximately 7 % of its turnover to R&D in 2018.
DEVA Holding completed year 2018 successfully ranking in second place, with 6.4% market share in terms of volume, according to IQVIA free market volume data (free market + tenders).
DEVA Holding has approximately 600 products in 13 therapeutic areas including Hematology & oncology, ophthalmology and respiratory system products amongst others creating difference by launching new products into market every single year.
DEVA production facilities have been approved and certified by EU GMP and US FDA with an annual output capacity of 515 million units. Manufacturing capacity allows production of different pharmaceutical forms at large scales:
• Tablets, Capsules
• Injectable Products (Ampoules, Vials)
• Eye Drops
• Sterile Pomads
• Gels & Ointments
• Syrups and Solutions
• Metered-Dose Inhalers (MDI) and Dry-Powder Inhalers (DPI)
The high quality of DEVA production facilities are endorsed by globally recognized certification bodies:
DEVA has three manufacturing facilities which are endorsed by internationally recognized certifications proving the high quality standards of DEVA.
• Semi-Solid Dosage Forms:
Creams, Gels, Ointments, Suppository
• Solid Dosage Forms:
• Liquid Dosage Forms:
Solutions, Suspensions, Syrups, Solutions and Suspensions for Nebulisers
• Metered-Dose Inhalers (MDI), Dry-Powder Inhalers (DPI)
• Separate Production Building for:
Cephalosporines (Tablets, Dry Syrups, Vials)
Penicillins (Tablets, Dry Syrups, Vials)
• Hormones (Tablets, Creams, Gels, Ointments, Vials, Drops)
• Separate Production Plant for Onctology Products (Tablets, Capsules)
• Separate Production Plant for Steril Oncology Products (Vials)
• Active Ingredient Synthesis (API)
Location: Turkey’s Largest Logistics Center
In 2018, Turkey’s largest pharmaceutical logistics center, started its operations with 32000 pallet capacity and received EU GMP approval
• Sterile liquids in ampoules and vials
• Lyophilized products in vials
• Small volume parenterals with blow fill seal technology
Unit doses (LDPE)
Multi doses (LDPE)
•Empty medical ampoule